Aug 12, 2020
Health Canada provides COVID-19 Interim Order approval for Bactiguard's endotracheal tubes
Jun 18, 2020
Aridis Pharmaceuticals to Discuss APEX(TM) in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th
May 12, 2020
Aridis Pharmaceuticals Announces First Quarter 2020 Results
May 12, 2020
Global Ventilator Associated Pneumonia (VAP) Pipeline Guide: Companies Involved in Therapeutics Development
May 04, 2020
Aridis Pharmaceuticals Enrolls Its First COVID-19 Patient in Ongoing Phase 3 AR-301 Clinical Trial in Ventilator Associated Pneumonia (VAP)
Feb 18, 2020
Aridis Pharmaceuticals to Host Investor Day Showcasing APEX(TM) Technology Platform and Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia
Oct 11, 2019
Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer
Sep 03, 2019
Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa
Jul 19, 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
Jun 27, 2019
Aridis Pharmaceuticals Receives Orphan Drug Designation for AR-501
Jun 10, 2019
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
May 14, 2019
Aridis Pharmaceuticals Announces First Quarter 2019 Results
Jan 24, 2019
Liberate Medical's VentFree(TM) Muscle Stimulator Receives Breakthrough Device Designation from the FDA to Reduce Mechanical Ventilation Duration
Jan 08, 2019
Ondine Biomedical CEO is Appointed to Canada's National Research Council (NRC)
Nov 24, 2017
Phase III study with Amikacin Inhale in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority